Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 801 - 825 of 1348 in total
Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed...
Approved
Investigational
Matched Description: … soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL ... in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid ... human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Biologics for Rheumatoid Arthritis Treatment …
Matched Products: … KEVZARA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG ... KEVZARA Solution for Injection in Pre-filled Pen 150mg ... KEVZARA Solution for Injection in Pre-filled Pen 200mg …
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells,...
Approved
Investigational
Matched Description: … and mantle cell lymphoma. ... Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma ... ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Products: … Retrox 3.5mg Powder for Solution for Injection ... MYBORTE POWDER FOR SOLUTION FOR INJECTION 3.5MG/VIAL ... BORTESUN POWDER FOR SOLUTION FOR INJECTION 3.5 mg …
Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal...
Approved
Matched Description: … It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan ... Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antimycotics for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … FUPASCIN POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 70MG/VIAL ... FUPASCIN POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIAL ... CASPODIN POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIAL …
Ampicillin is a semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.
Approved
Vet approved
Matched Mixtures name: … SULBACTER POWDER FOR SOLUTION FOR INJECTION or INFUSION 3g/vial ... SULBACTER POWDER FOR SOLUTION FOR INJECTION or INFUSION 1.5g/vial ... UNASYN 750 FOR INJECTION …
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … SANPICILLIN FORTE ... Ampicillin for Injection ... Ampicin for Injection 250mg …
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability,...
Approved
Investigational
Matched Description: … VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to ... , and migration of human endothelial cells. ... By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML ... CYRAMZA CONCENTRATE FOR SOLUTION FOR INFUSION 500MG/50ML ... Cyramza 100mg/10ml concentrate for solution for infusion …
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Approved
Matched Description: … It is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU. …
Matched Mixtures name: … LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 10MCG AND 20MCG (50mcg/mL and 100mcg/mL) ... LYXUMIA SOLUTION FOR INJECTION IN PRE-FILLED PEN 10MCG AND 20MCG (50mcg/mL and 100mcg/mL) ... Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... insulin glargine and lixisenatide …
Matched Products: … LYXUMIA (SOLUTION FOR INJECTION 10 MCG) ... LYXUMIA (SOLUTION FOR INJECTION 20 MCG) ... Lyxumia 20mcg Solution for Injection …
Experimental
Matched Name: … 2'-O-Methyl-3'-Methyl-3'-Deoxy-Arabinofuranosyl-Thymine-5'-Phosphate
Experimental
Matched Name: … (2R)-2-Acetamido-3-(octadecyloxy)propyl 2-(methylsulfanyl)ethyl hydrogen phosphate
Experimental
Matched Name: … 4-(6-CHLORO-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL) BUTYL PHOSPHATE
Experimental
Matched Name: … (3-Formyl-but-3-Enyl)-Phosphonic Acid …
Experimental
Matched Name: … 5-Formyl-2'-deoxy-cytidine-5'-monophosphate …
Matched Iupac: … {[(2R,3S,5R)-5-(4-amino-5-formyl-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy}phosphonic …
Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action.
Investigational
Matched Description: … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and
Matched Products: … Cimalgex 30mg chewable tablets for dogs ... Cimalgex 80mg chewable tablets for dogs ... Cimalgex 8mg chewable tablets for dogs …
Experimental
Matched Name: … 4-Carbamoyl-1-Beta-D-Ribofuranosyl-Imidazolium-5-Olate-5'-Phosphate
Experimental
Matched Name: … (1Z)-2-HYDROXY-3-OXOHEX-1-EN-1-YL DIHYDROGEN PHOSPHATE
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour...
Approved
Investigational
Matched Description: … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint ... unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and ... ] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage small …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML ... IMFINZI CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION 50 MG/ML …
Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to...
Approved
Investigational
Matched Description: … [L14339] It was first authorized for use in the US in November 2001 and in Europe in April 2002. ... [A447] Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic …
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … ERTAPENEM MEVON POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1G/VIAL ... Ertapenem for Injection ... INVANZ FOR INJECTION 1 g/vial …
Polyvinyl alcohol is a water-soluble synthetic polymer obtained by polymerization of vinyl alcohol. It has varying roles in commercial and industrial applications such as papermaking, textiles, and printing. Polyvinyl alcohol is found in ophthalmic solutions as a lubricant to prevent irritation or to relieve dryness of the eyes .
Approved
Matched Description: … It has varying roles in commercial and industrial applications such as papermaking, textiles, and printing …
Matched Mixtures name: … Murine Tears for Dry Eyes ... Murine Plus for Dry Eyes Redness Relief …
Matched Products: … Liquifilm Forte 3% ... Artificial Tears for Dry Eyes …
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Approved
Investigational
Matched Description: … It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. …
Matched Products: … Desferal 500mg Powder for Solution for Injection ... Deferoxamine Mesylate for Injection ... DBL DESFERRIOXAMINE MESYLATE FOR INJECTION BP 500 mg/vial …
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that...
Approved
Investigational
Matched Description: … was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and ... [L9392] The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous ... Ustekinumab is currently the first and only approved biologic therapy for ulcerative colitis that targets …
Matched Categories: … Biologics for psoriasis treatment ... Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …
Matched Products: … STELARA CONCENTRATE FOR SOLUTION FOR INFUSION 130MG/26ML ... STELARA 130mg/26mL Concentrate for Solution for Infusion ... Solution for Injection 90mg/1ml …
A vitamin-like antioxidant.
Approved
Investigational
Nutraceutical
Matched Synonyms: … Thioctic acid D-form
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is...
Approved
Investigational
Matched Description: … Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
Matched Products: … IXEMPRA FOR INJECTION 15 MG ... IXEMPRA (FOR INJECTION 15 MG) ... IXEMPRA FOR INJECTION 45 MG …
Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … Vectibix Concentrate for Solution for Infusion 100 mg/vial ... Vectibix 100mg Concentrate for Solution for Infusion …
Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R,...
Approved
Investigational
Matched Description: … It is an afucosylated IgG which gives it high affinity for the FcγRIIIα receptor in natural killer cells ... , macrophages and neutrophils. ... global biologic research and development arm. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs for Obstructive Airway Diseases …
Matched Products: … Fasenra 30 mg solution for injection in pre-filled syringe ... Fasenra 30mg Solution for Injection in Pre-filled Pen ... FASENRA SOLUTION FOR INJECTION 30MG/ML (AUTOINJECTOR PEN) …
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. The antibody is specifically...
Approved
Investigational
Matched Description: … It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who ... candidates for cytotoxic chemotherapy [A98]. ... By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL …
Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects. Inotuzumab ozogamicin was first...
Approved
Investigational
Matched Description: … [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly ... [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL …
Displaying drugs 801 - 825 of 1348 in total